INSP: CMS Coding Clarity Will Support Future Reimbursement And Earnings Power

Analysts have reset the fair value estimate for Inspire Medical Systems to $79.42, down from $124.40, as they factor in lower revenue growth assumptions, a slimmer future P/E of 26.47 instead of 45.15, and updated views on reimbursement clarity following recent CMS coding decisions.

Analyst Commentary

Recent Street research around Inspire Medical Systems has centered on reimbursement clarity, coding changes from CMS and how these factors feed into execution risk and valuation. Analysts are split, with some focusing on clearer reimbursement visibility and others emphasizing reduced earnings power versus prior expectations.

Bullish Takeaways

Bullish analysts view the CMS decision to map Inspire V specific C-codes at parity with HCPCS 64582 and to assign the new hypoglossal nerve stimulation codes to APC 5465 as supportive for continuity in hospital reimbursement. They see this as helpful for defending procedure economics in their models.
The confirmation that the hospital facility fee remains at roughly US$31,500 and that Inspire Medical’s overall reimbursement is essentially unchanged is seen by these analysts as reducing downside risk that could have pressured margins and capacity for reinvestment.
Some bullish analysts describe the introduction of six new HCPCS codes and product specific coding for Inspire V as a directionally positive step, as it may help bring more structure to future payment decisions and reduce uncertainty that had weighed on sentiment.
Where analysts assume reimbursement stability holds, they frame the story more around execution on guidance and procedure volumes. They view these as more manageable drivers for fair value compared with the prior overhang around coding.

Bearish Takeaways

Bearish analysts have reduced price targets materially and, in some cases, lowered ratings after the company cut its FY26 sales guidance. They state that this revision raises new uncertainties for medium term growth assumptions and justifies more conservative valuation multiples.
Several firms have trimmed targets by sizeable dollar amounts and issued downgrades, signaling concern that earlier revenue and earnings trajectories embedded in their models may no longer be appropriate given updated company guidance.
Analysts flag unresolved questions around the physician fee and the impact of the 52 modifier, with some indicating that further MAC guidance will be important before they can gain comfort around the full economics of the procedure for all stakeholders.
Where estimates are now set closer to or below the low end of management’s revised outlook, bearish analysts see a risk that execution against those new benchmarks could still be challenging. This keeps them cautious on growth, P/E support and the potential for multiple compression if expectations reset again.

What's in the News

Inspire Medical Systems revised its full year 2026 revenue outlook to a range of US$950 million to US$1.0 billion, with expected net income per diluted share between US$1.23 and US$1.81, citing coding uncertainty and different possible outcomes tied to CPT code 64582 with the 52 modifier and related physician reimbursement rates (Company guidance).
The company provided revenue guidance for Q4 2025 of US$268.9 million to US$269.1 million, for full year 2025 of US$911.8 million to US$912.0 million, and for full year 2026 of US$1,003 million to US$1,013 million (Company guidance).
Inspire Medical Systems completed a share repurchase of 1,076,225 shares, representing 3.67% of shares, for US$99.99 million under the buyback announced on August 11, 2025. This included 523,802 shares, or 1.8%, repurchased for US$50 million in Q4 2025 (Buyback update).
Matt Osberg was appointed Chief Financial Officer, with a start date of January 19, 2026, bringing over 20 years of experience in global financial leadership, corporate governance and corporate transformation roles across several companies (Executive announcement).
The company plans to seek shareholder approval at the 2026 annual meeting to amend its Seventh Amended and Restated Certificate of Incorporation to declassify the Board and move to annual director elections after a phase in period. It also plans to align director removal provisions with Delaware General Corporation Law, with related Amended and Restated Bylaws approved by the Board subject to that vote (Corporate governance filing).

Valuation Changes

Fair Value: reset from $124.40 to $79.42, a reduction of about 36% in the modelled estimate.
Discount Rate: moved slightly higher from 7.67% to 7.72%, implying a modestly higher required return on the shares in the analysis.
Revenue Growth: trimmed from 11.09% to 8.01%, reflecting a lower assumed growth rate for future dollar revenue.
Net Profit Margin: raised from 7.67% to 8.48%, indicating a higher expected share of dollar earnings from each dollar of revenue in the updated model.
Future P/E: reduced from 45.15x to 26.47x, indicating a lower valuation multiple applied to projected earnings.

7 views

Key Takeaways

Transitory operational delays are expected to resolve soon, positioning the company for accelerated growth as new system adoption and reimbursement improvements unfold.
Market expansion and clinical enhancements will boost provider capacity and adoption, supporting sustained long-term revenue growth amid rising demand for sleep health solutions.
Execution delays, increased competition, operational missteps, and evolving market dynamics threaten revenue stability, margins, and long-term growth prospects for Inspire Medical Systems.

Catalysts

About Inspire Medical Systems

A medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally.What are the underlying business or industry changes driving this perspective?

The recent delay in transitioning centers to the Inspire V next-generation system-including slower onboarding, delayed SleepSync implementation, and the Medicare billing update-are transitory issues; as these barriers resolve (with Medicare billing now live and most centers expected to complete onboarding by end of Q3), procedure volumes and revenue growth are positioned to reaccelerate in 2026 as pent-up demand is realized.
Expanded coverage and proposed reimbursement increases for Inspire's procedures (notably the expected 2026 Medicare OPPS rule enhancements and near-complete payer coverage of the new CPT code) will reduce patient out-of-pocket costs and incentivize additional adoption, supporting both revenue growth and longer-term earnings visibility.
The second half of 2025 will see a ramp in marketing and new center expansion following a purposeful pause in H1 amid the Inspire V launch; this resurgence in patient education, awareness campaigns, and provider capacity building should drive higher procedure volumes and top-line acceleration into 2026 and beyond.
Inspire V's clinical enhancements-shorter procedure times (20% reduction), elimination of the pressure-sensing lead, and workflow simplification-are already increasing implant throughput at transitioned centers (20%+ higher volumes), suggesting a meaningful lift in provider capacity and future revenue as the full installed base adopts these improvements.
Increasing prevalence of obstructive sleep apnea and rising global focus on sleep health are fueling ongoing expansion of Inspire's addressable market; as obesity rates and aging populations climb, structural demand tailwinds are likely to translate into sustained long-term procedure and revenue growth for the company.

Inspire Medical Systems Earnings and Revenue Growth

Inspire Medical Systems Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

Analysts are assuming Inspire Medical Systems's revenue will grow by 8.0% annually over the next 3 years.
Analysts assume that profit margins will shrink from 15.9% today to 8.5% in 3 years time.
Analysts expect earnings to reach $97.5 million (and earnings per share of $3.79) by about April 2029, down from $145.4 million today. However, there is a considerable amount of disagreement amongst the analysts with the most bullish expecting $130.1 million in earnings, and the most bearish expecting $63.8 million.
In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 26.5x on those 2029 earnings, up from 10.9x today. This future PE is lower than the current PE for the US Medical Equipment industry at 26.6x.
Analysts expect the number of shares outstanding to decline by 3.07% per year for the next 3 years.
To value all of this in today's terms, we will use a discount rate of 7.72%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

The slower-than-expected rollout of Inspire V, driven by delays in center training, contracting, onboarding, and technical hurdles with implementing SleepSync, has materially reduced near-term revenue growth rates and deferred volume expansion, increasing execution risk and potentially causing a protracted recovery in revenue and margins into 2026.
Increased dependence on a single primary product (Inspire V) and the complexities of transitioning from Inspire IV introduce risks of technological obsolescence, operational missteps, or further customer delays, which could threaten stability of long-term revenue growth and earnings visibility if competitive alternatives emerge or adoption lags.
The need for higher patient marketing and territory expansion spend in the face of revenue pressure has driven operating expenses up faster than revenue growth, compressing net margins and earnings per share; this cost trend could persist if Inspire Medical Systems must continue elevated spend to regain growth momentum and offset competitive threats.
The potential for structural changes in sleep apnea therapy-such as increased use of GLP-1 drugs for weight loss (reducing OSA prevalence or changing patient eligibility) and broader adoption of non-invasive digital health solutions-could permanently shrink Inspire's addressable market or reduce demand for surgically implanted devices, thereby impacting long-term revenue growth and profitability.
Changes in reimbursement dynamics, especially regarding Medicare and shifting CPT codes, have created temporary barriers but also hint at a long-term risk: payer and regulatory pressure could limit coverage, reduce pricing power, or discourage high-volume implanters from treating certain patient groups-putting sustained pressure on both revenue and margins over time.

Valuation

How have all the factors above been brought together to estimate a fair value?

The analysts have a consensus price target of $79.42 for Inspire Medical Systems based on their expectations of its future earnings growth, profit margins and other risk factors.
However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $120.0, and the most bearish reporting a price target of just $66.0.
In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $1.1 billion, earnings will come to $97.5 million, and it would be trading on a PE ratio of 26.5x, assuming you use a discount rate of 7.7%.
Given the current share price of $54.99, the analyst price target of $79.42 is 30.8% higher. Despite analysts expecting the underlying business to decline, they seem to believe it's more valuable than what the market thinks.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on Inspire Medical Systems?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

Sector Dislocations And Transitory Headwinds Will Create Long-Term Upside Opportunity